Diaceutics PLC

AIM:DXRX Stock Report

Market Cap: UK£98.0m

Diaceutics Valuation

Is DXRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DXRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DXRX (£1.16) is trading below our estimate of fair value (£1.32)

Significantly Below Fair Value: DXRX is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DXRX?

Key metric: As DXRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DXRX. This is calculated by dividing DXRX's market cap by their current revenue.
What is DXRX's PS Ratio?
PS Ratio3.8x
SalesUK£26.10m
Market CapUK£97.99m

Price to Sales Ratio vs Peers

How does DXRX's PS Ratio compare to its peers?

The above table shows the PS ratio for DXRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.9x
HVO hVIVO
2x4.4%UK£134.7m
MXCT MaxCyte
7.9x20.5%UK£286.9m
ERGO Ergomed
4.6x8.8%UK£701.1m
C4XD C4X Discovery Holdings
1.2x-52.4%UK£30.3m
DXRX Diaceutics
3.8x1.8%UK£98.0m

Price-To-Sales vs Peers: DXRX is expensive based on its Price-To-Sales Ratio (3.8x) compared to the peer average (3.7x).

Price to Sales Ratio vs Industry

How does DXRX's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
DXRX 3.8xIndustry Avg. 4.4xNo. of Companies9PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DXRX is good value based on its Price-To-Sales Ratio (3.8x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is DXRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DXRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: DXRX is expensive based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DXRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.16
UK£1.75
+51.2%
8.4%UK£2.00UK£1.60n/a5
Nov ’25UK£1.22
UK£1.75
+43.7%
8.2%UK£2.00UK£1.60n/a5
Oct ’25UK£1.34
UK£1.75
+30.8%
8.2%UK£2.00UK£1.60n/a5
Sep ’25UK£1.33
UK£1.75
+31.8%
8.2%UK£2.00UK£1.60n/a5
Aug ’25UK£1.30
UK£1.75
+34.3%
8.2%UK£2.00UK£1.60n/a5
Jul ’25UK£1.28
UK£1.73
+35.4%
9.7%UK£2.00UK£1.50n/a5
Jun ’25UK£1.33
UK£1.68
+26.6%
11.7%UK£2.00UK£1.45n/a5
May ’25UK£0.99
UK£1.67
+67.4%
11.9%UK£2.00UK£1.45n/a5
Apr ’25UK£1.07
UK£1.67
+55.7%
11.9%UK£2.00UK£1.45n/a5
Mar ’25UK£0.94
UK£1.67
+78.2%
11.9%UK£2.00UK£1.45n/a5
Feb ’25UK£1.04
UK£1.67
+60.2%
11.9%UK£2.00UK£1.45n/a5
Jan ’25UK£0.87
UK£1.75
+101.5%
11.6%UK£2.00UK£1.50n/a3
Dec ’24UK£0.93
UK£1.75
+89.5%
11.6%UK£2.00UK£1.50n/a3
Nov ’24UK£0.85
UK£1.72
+102.4%
10.8%UK£2.00UK£1.50UK£1.224
Oct ’24UK£1.05
UK£1.72
+63.8%
10.8%UK£2.00UK£1.50UK£1.344
Sep ’24UK£1.05
UK£1.71
+63.3%
12.5%UK£2.00UK£1.50UK£1.333
Aug ’24UK£1.03
UK£1.71
+66.5%
12.5%UK£2.00UK£1.50UK£1.303
Jul ’24UK£0.85
UK£1.71
+100.8%
12.5%UK£2.00UK£1.50UK£1.283
Jun ’24UK£0.81
UK£1.71
+112.0%
12.5%UK£2.00UK£1.50UK£1.333
May ’24UK£1.00
UK£1.71
+70.7%
12.5%UK£2.00UK£1.50UK£0.993
Apr ’24UK£1.02
UK£1.71
+67.3%
12.5%UK£2.00UK£1.50UK£1.073
Mar ’24UK£1.14
UK£1.71
+49.7%
12.5%UK£2.00UK£1.50UK£0.943
Feb ’24UK£1.07
UK£1.71
+60.3%
12.5%UK£2.00UK£1.50UK£1.043
Jan ’24UK£0.76
UK£1.59
+110.6%
18.3%UK£2.00UK£1.35UK£0.873
Dec ’23UK£0.76
UK£1.59
+110.6%
18.3%UK£2.00UK£1.35UK£0.933
Nov ’23UK£0.79
UK£1.59
+101.3%
18.3%UK£2.00UK£1.35UK£0.853

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.80

7D

1.9%

1Y

12.1%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%